ACTIVATION OF THE PHOSPHOLIPASE CYCLOOXYGENASE CASCADE IN THE RABBIT CORNEA BY PLATELET-ACTIVATING-FACTOR IS CHALLENGED BY PAF RECEPTOR ANTAGONISTS

被引：12

作者：

HURST, JS ^{[1
]}

BAZAN, HEP ^{[1
]}

机构：

[1] LOUISIANA STATE UNIV,MED CTR,SCH MED,CTR EYE,NEW ORLEANS,LA 70112

来源：

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS | 1995年 / 11卷 / 03期

关键词：

D O I：

10.1089/jop.1995.11.329

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Platelet-activating factor (PAF) is a potent lipid inflammatory mediator which is generated in the cornea after injury. Its activity is regulated by interaction with specific receptors. The binding of PAF to its receptors initiates biochemical sequences that cluminate in the release of additional lipid mediators. An arachidonoyl-dependent phospholipase A(2) is activated to release arachidonic acid from membrane phospholipids, especially phosphatidylcholine and ethanolamine. Arachidonic acid is then predominantly metabolized by the cyclooxygenase pathway to prostagiandins F-2 alpha, E(2) and D-2, whereas the lipoxygenase pathway is not influenced by PAF. The release of arachidonic acid and prostaglandins stimulated by PAF is challenged by the PAF receptor antagonists BN 50727 and BN 50730. PAF acting intracellularly may also induce the synthesis of cyclooxygenase, presumably the 'inducible' isoform PGHS2, which has been implicated in the inflammatory response. Thus, the therapeutic use of PAF receptor angatonists could be potentially beneficial in the management of ocular inflammatory disease.

引用

页码：329 / 337

页数：9

共 39 条

[11]

Tselepsis A.D., Tsoukatos S.D., Droudes C., Donas A., Evangelou A., Platelet response to the aggregating effect of platelet-activating factor ex vivo in patients with acute myocardial infarction, Eur. J. Clin. Invest., 21, pp. 490-496, (1991)

[12]

Jouvin-Marche E., Poitevin B., Benveniste J., Platelet-activating factor is an activator of neutrophil function, Agents. Actions., 12, pp. 716-720, (1982)

[13]

Gandi C.R., Olson M.S., PAF effects on transmembrane signalling pathways in tat Kupffer cells, Lipids, 26, pp. 1038-1043, (1991)

[14]

Bazan H.E.P., Reddy S.T.K., Lin N., Platelet-activating factor (PAF) accumulation correlates with injury in the cornea, Exp. Eye Res., 52, pp. 481-491, (1991)

[15]

Dharma S., Bazan H.E.P., Peymen G.A., Atef M.S.E., Production of platelet-activating factor in photocoagulated retinas, Curr. Eye Res., 10, pp. 1031-1035, (1991)

[16]

Rubin R.M., Samples J.R., Rosenbaum J.T., Prostaglandin-independent inhibition of ocular vascular permeability by a platelet-activating factor antagonist, Arch. Ophthalmol., 106, pp. 1116-1120, (1988)

[17]

Lin N., Bazan H.E.P., Braquet P., Bazan N.G., Prolonged effect of a new platelet-activating factor antagonist on ocular vascular permeability in an endotoxin model of uveitis, Curr. Eye Res., 10, pp. 19-24, (1991)

[18]

Chan C.C., McKee K., Tagari P., Chee P., Ford-Hutchinson A., Eosinophil-eicosanoid interactions: Inhibition of eosinophil chemotaxis in vivo by a LD4-receptor antagonist, Eur. J Pharmacol., 191, pp. 273-280, (1990)

[19]

Stock E.L., Roth S.I., Kim E.D., Walsh M.K., Thamman R., The effect of platelet-activating factor (PAF), histamine and ethanol on vascular permeability of the guinea pig conjunctiva, Invest. Ophthal, Vis. Sci., 31, pp. 987-992, (1991)

[20]

Muller A., Meynier G., Bonne C., PAF-induced conjunctivitis in the rabbit is mediated by peptido-leukotrienes, J. Ocul. Pharmacol, 6, pp. 227-232, (1990)

← 1 2 3 4 →